BASIC STUDY OF CLINICAL APPLICATION OF HUMAN MONOCLONAL ANTIBODY TO RAS ONCOGENE PRODUCT

研究了胰腺癌和结肠癌患者对ras致癌产物的免疫反应。胰腺癌患者血清抗ras抗体阳性率显著高于对照组（80%,4/5,p< 0）。结肠癌(40%,51/150,p< 0。与正常供者相比（55,2 /40）。抗ras抗体识别p21ras蛋白的正常或突变片段，73%的结肠癌患者有p2lras蛋白羧基末端的抗体。胰腺癌患者特异性ras肽的T淋巴细胞检出率明显高于胰腺癌患者（40%,6/15,p< 0.05）。l)和结肠癌(24%,6/25,p< 0。与正常供体相比（0%,0/20）。我们试图诱导ras肽的细胞毒性T淋巴细胞，并发现可以从3例胰腺癌患者中的1例外周血淋巴细胞中诱导p2lras蛋白正常羧基端特异性CD4+ CTL。结果表明，基于ras癌蛋白血清抗体的存在诊断和针对ras癌蛋白的CTL免疫治疗是未来胰腺癌和结肠癌患者的有希望的医学治疗方法。

Immune responses to ras oncogenic products were studied in pancreatic and colon cancer patients. Positive rates for serum anti-ras antibody were significantly higher in patients with pancreatic cancer (8O%, 4/5, p<O.05) and colon cancer (40%, 51/150, p<O.Ol) as compared to normal donors (55, 2/40). The anti-ras antibodies recognized normal or mutated segments of p21ras protein, and 73% of colon cancer patients had antibodies to the carboxyl terminus of p2lras protein. T lymphocyte detection rates for specific ras peptides were significantly higher in patients with pancreatic cancer (40%, 6/15, p<O.Ol) and colon cancer (24%, 6/25, p<O.Ol) as compared to normal donors (0%, 0/20). We attempted to elicit cytotoxic T lymphocyte for ras peptides, and found the CD4+ CTL specific for the normal carboxyl terminus of the p2lras protein could be elicited from peripheral blood lymphocytes from one of the three patients with pancreatic cancer. The results suggest that diagnosis of the existence, based on serum antibodies to ras oncogenic proteins, and immunotherapy with CTL specific for ras oncogenic proteins are promising future medical treatments for pancreatic and colon cancer patients.